A review about the impact of multiple sclerosis on health-related quality of life

JULIÁN BENITO-LEÓN†*, JOSÉ MANUEL MORALES‡, JESÚS RIVERA-NAVARRO§ and ALEX J. MITCHELL¶

† Department of Neurology, Móstoles General Hospital, Móstoles, Madrid, Spain
‡ Department of Research, Ministry of Labour and Social Affairs, Madrid, Spain
§ Social Work Faculty, Veracruzana University, Veracruz, Mexico
¶ Academic Unit of Psychiatry, University of Leeds, Leeds, UK

Accepted for publication: July 2003

Abstract

Purpose: There is increasing recognition that the global wellbeing of patients with chronic neurological disease is an important outcome in research and clinical practice alike. Many studies involving individuals with multiple sclerosis have demonstrated that the overall wellbeing is not a simple manifestation of impairment or disability. The strongest correlations with health-related quality of life appear to be patient rated emotional adjustment to illness and patient rated handicap. In recent years, health-related quality of life questionnaires that measure the physical, social, emotional, and occupational impact of illness have been developed and validated in populations with MS. Most questionnaires are now available in a range of languages. This development is likely to lead to increasing recognition of neuropsychiatric complications of MS in clinical practice and better quantification of treatment responses in clinical trials.

Conclusion: Further work is required to decide which scale is most suited to which purpose. Assessment of multiple sclerosis-specific health-related quality of life should be included in future clinical trials to provide a complete picture of patients' health status.

Introduction

Multiple sclerosis (MS) is a chronic neurological disease characterized by macroscopic and microscopic areas of demyelination, linked with a broad spectrum of physical and social impairments. The combination of a progressive and unpredictable disease process creates an uncommonly stressful illness which powerfully impacts upon the quality of life (QoL) of both the patients and their relatives.1–3

QoL is not a new concept and early reference can be found in Greek literature. In its widest sense it embraces all aspects of well being and includes social, emotional, economic and cultural facets of our lives. Health Related QoL (HRQoL), as distinct from general QoL, is conceptualized as those aspects of life quality or function which are influenced by health status. This is broadly compatible with the World Health Organisation definition of health, namely that health is ‘a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity’. However, the term HRQoL is more specific and is based on health dimensions which can be measured. This ability to measure HRQoL in individuals over time brings important benefits. Quantifying HRQoL in different populations can identify subgroups with poor physical or mental health and can assist with interventions that may improve their health. Assessment of HRQoL is increasingly important for clinical research, clinical practice, and the decision-making process in health policy.4–7

The interest in HRQoL in MS is very recent. For many years research on the impact of MS was limited to an examination of the concepts of impairment and disability.8 The first paper that analysed the HRQoL in MS patients was published in 1992. In this landmark study, HRQoL was measured in 68 patients with MS, 164 patients with inflammatory bowel disease, and 75 patients with rheumatoid arthritis.9 HRQoL was lowest in the MS group. Over the last decade the literature on HRQoL in MS has grown exponentially. This has encompassed a growth of descriptive studies about the physical, emotional and social consequences of MS; the development of MS specific HRQoL instruments;
and most recently an examination of the effects of disease-modifying therapies on HRQoL in MS patients. The purpose of this article is to review this literature concerning the impact of MS on HRQoL.

Method

We conducted a literature review using the principles of evidence based medicine. We used the text search terms (multiple sclerosis or MS) and (quality of life or QoL or handicap or function or participation) to identify all relevant English papers between 1966 and April 2003. We searched the electronic databases Medline, Embase, Web of Science and PsychInfo. We also contacted experts in the field and hand-searched a number of neurological journals. We excluded studies that did not discuss QoL and articles without primary data (review articles). The search identified approximately 330 published papers covering the major studies on this topic, of which 89 had enough suitable information to be discussed in this review.

THE INFLUENCE OF MULTIPLE SCLEROSIS ON HEALTH-RELATED QUALITY OF LIFE

MS is a condition that has great potential to negatively affect HRQoL. Yet, it is important to acknowledge the wide range of individual differences in emotional and psychological adjustment to disease, even after the most disabling of impairments. People with MS report a lower life satisfaction than people without illness. They also report a lower satisfaction with life than people with several chronic illnesses including inflammatory bowel disease and rheumatoid arthritis as well as epilepsy and diabetes. Several features of MS may uniquely contribute to low HRQoL. Firstly, MS affects the integrity of normal physiological functioning in a diverse number of areas including neurological function (motor and sensory disturbances, sphincter problems and sexual dysfunction), psychiatric function (cognitive impairment, mood disorder and psychosis), and other areas (for example, mobility and fatigue). Secondly, the disease is diagnosed primarily in young adults, which maximally influences productivity and personal development. Thirdly, MS has an unpredictable course, in which relapses and future disability are difficult for sufferers to anticipate. This makes it difficult for patients to maintain a sense of control over their disease. Fourthly, there is currently limited evidence for disease-modifying treatment and no possibility of cure. Finally, there are problems accessing the latest treatment due to inequalities in health care provision and there is a risk of drug-induced adverse effects. Thus it is imperative to be aware of the wider needs of patients. Yet, paradoxically, the effect of MS on HRQoL has often been widely overlooked in routine clinical practice and in most clinical trials. Instead, physicians have concentrated on the assessment of physical disability in MS, perhaps best exemplified by the Expanded Disability Status Scale of Kurtzke (EDSS). Although the EDSS was a major breakthrough it is now recognized to have psychometric limitations, including relatively poor responsiveness, and a narrow focus. Subsequently other scales have been devised, such as the Multiple Sclerosis Functional Composite. This is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). However, disability and handicap scales such as the EDSS and the Functional Composite have other limitations. They rely on assessment by neurologists rather than patients and they also omit domains of health that contribute to overall QoL. These are important points as clinicians and patients do not agree on what aspects of the disease are most important. Research shows that clinicians are most concerned about the physical manifestations of disease, whereas patients tend to identify role limitations, cognition and emotional problems as the most significant influences upon wellbeing. A further aspect overlooked by conventional scales is the huge burden on families and informal caregivers. This burden is under-studied and under-reported but is comparable to the burden experienced by relatives of neurodegenerative disease. There is probably a relationship between carer and patient distress. This suggests that the opinion of MS patients and caregivers should be considered in clinical trials and that outcomes should be widened to include domains which affect patient distress and family stress, a philosophy incorporated within the concept of HRQoL. As a complement to the assessment of physical disability, physicians must also recognise the need for instruments to evaluate general health, emotional and social functioning. This appreciation has resulted in the development of a series of new instruments to assess HRQoL some of which are generic and some of which are specific to MS.

GENERIC HRQOL INSTRUMENTS

Generic measures of HRQoL are measures that were developed without a specific disease in mind and are therefore applicable to a wide range of populations.
The main advantage of generic HRQoL instruments is their broad coverage and the fact that they allow comparisons of different populations across studies. A significant disadvantage is that they may not address topics of particular relevance to MS patients such as cognitive complaints. A consequence of their relatively poor coverage of specific symptoms in MS is that they are less responsive to treatment-induced changes than MS-specific measures. Nevertheless, studies involving generic HRQoL instruments have provided important data. These include:

1. The initial identification of broad areas impacted by MS that had not previously been considered by conventional clinical scales.10, 16, 18, 19, 28–32
2. The demonstration that the HRQoL in patients with MS is, on average lower than HRQoL in control subjects or in patients with other diseases.9, 13, 14, 33, 34
3. Assessment of MS HRQoL in clinical trials.35–40

Table 1 shows a selection of the generic HRQoL instruments that have been used in MS studies to date. The most widely used generic instrument is the SF-36, which is generally considered to be the gold standard generic measure of health status and has been validated cross-culturally in MS.44, 46–52 The SF-36 is a broad measure of disease impact rated by sufferers themselves. In MS all eight dimensions of QoL in the SF-36 are reduced compared with the general population.29 However, longitudinal studies have highlighted several limitations of the SF-36, including a relatively poor responsiveness and contamination from changes in physical disability.53 Moreover, when using the SF-36 in MS patients, summary scores should be reported with caution.54 On the other hand, the SF-36 mental health summary scales appear to overestimate mental health in MS sufferers, despite a high prevalence of emotional and cognitive disorders.55

### Types of MS-Specific HRQoL Instruments

New MS-specific measures of HRQoL have been developed in an attempt to reduce the weaknesses inherent in the generic instruments (table 2). Once developed, further work is required to translate them into different languages, or explore their validity in different settings.

Multiple Sclerosis Quality of Life 54

The MSQOL-54 was the first MS-specific HRQoL instrument.56–59 It consists of a generic instrument
RAND 36-Item Health 1.0\textsuperscript{60} as a core measure, supplemented with 18 additional items in the areas of health distress (four items), sexual function (four items), satisfaction with sexual function (one item), overall quality of life (two items), cognitive function (four items), energy (one item), pain (one item), and social function (one item). The generic component enables a comparison of HRQoL in MS patients to those of other patient populations and to the general population. The final MSQOL-54 instrument, contains 52 items distributed into 12 subscales along with two summary scores, and two additional single-item measures. The subscales are: physical function, role limitations – physical, role limitations – emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. The summary scores are the physical health composite summary and the mental health composite summary. The single item measures are satisfaction with sexual function and change in health. This instrument, which was validated in one study including 183 MS patients, has a good internal consistency and test-retest reliability,\textsuperscript{56} but its validity and sensitivity to change has been criticised.\textsuperscript{61}

Disability and Impact profile

The Disability & Impact profile (DIP) has been used in several studies.\textsuperscript{30, 62–66} This instrument, which was validated in a sample of 73 MS patients, contains three symptoms questions (pain, visible deformities and worry about deterioration), as well as 36 questions in five areas: mobility, self-care, communication, social activities and psychological status. The results are presented in a profile of weighted scores that take into consideration the ‘(dis)ability’ and ‘impact’ aspects. By means of this profile and by means of so-called major disruptions of HRQoL, which are defined as a loss on weighted score on more than 50\%, the DIP provides indications for treatment and care. Internal consistency and test reliability are high for all scales of the DIP.\textsuperscript{30, 62–66}

Functional Assessment of Multiple Sclerosis

The original version of the Functional Assessment of Multiple Sclerosis (FAMS) instrument, which was validated in one sample of 433 MS patients, comprises 59 items capturing six main QoL domains: Mobility (7 items), Symptoms (7 items), Emotional Well-being (7 items), General Contentment (7 items), Thinking/Fatigue (9 items) and Family/Social Well-being (7 items).
All six FAMS subscales (44 items total) demonstrated very good reliability. Areas of concern to MS patients that do not fall in these six general domains are included in the Additional Concerns subscale (15 items). An analysis of this FAMS version, applied in a sample of 308 Spanish MS patients, showed high internal consistency reliability if eight additional MS-specific items, which had been initially excluded from the original version, were included. The main limitation of the original FAMS is that it is unduly weighted toward psychosocial consequences of disease. In contrast, the Spanish modified version of the FAMS instrument includes additional items about MS symptoms, which increases its validity and range of coverage.

In a recent study, FAMS instrument has been recommended for measuring QoL in MS patients instead of the MSQoL-54, since this latter instrument suffers from floor effects on physical health subscales. The original version of the FAMS is a very useful disease-targeted instrument to evaluate MS patients' HRQoL. However, we feel that the modified FAMS offers a more holistic assessment of neurological symptoms and psychosocial complaints associated with MS in line with published recommendations regarding specific HRQoL instruments.

**Hamburg Quality of Life Questionnaire in Multiple Sclerosis**

The Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS, in German) comprises 38 items. This instrument was validated in one study that included 237 MS patients. Validity was supported by correlation with FAMS. Reliability was high and satisfied psychometric standards. No floor or ceiling effects have been found in either of the HAQUAMS subscales. However, there is, as yet, no data about sensitivity to change. Of note, the HAQUAMS discriminated between MS patients with and without cognitive impairment.

**Leeds Multiple Sclerosis Quality of Life**

The Leeds Multiple Sclerosis Quality of Life (LMSQoL) is a new eight-item instrument with a good internal consistency and test-retest reliability. Moreover, there are minimal floor or ceiling effects for the scale. The instrument is also easy to use and practical to administer in clinic or as a postal questionnaire. It also measures a construct related to well-being, and thus provides an useful adjunct to the measurement of outcome in MS.

**Multiple Sclerosis Impact Scale**

The Multiple Sclerosis Impact Scale (MSIS-29) consists of 29 items that measure the physical (20 variables) and psychological (nine variables) impact of MS. The instrument, which was validated in 766 MS patients, has shown good validity, small floor and ceiling effects, high internal consistency, high test re-test reliability and preliminary evidence of good responsiveness. These results suggest that this instrument is a clinically useful and scientifically robust patient-based outcome measure. A recent study has demonstrated that the psychometric properties of the MSIS-29 are consistent across hospital based samples, and similar to those in the community samples.

**Multiple Sclerosis Quality of Life Inventory**

The Multiple Sclerosis Quality of Life Inventory (MSQLI) is a modular MS-specific HRQoL instrument consisting of the Health Status Questionnaire (SF-36), supplemented by nine symptom-specific measures (covering fatigue, pain, bladder function, bowel function, emotional status, perceived cognitive function, visual function, sexual satisfaction, and social relationships). The MSQLI was validated in one study that included 300 MS patients. The level of validation was extensive, showing that the internal consistency of the total MSQLI and the subscales was good, with one exception (social relationships), and that the instrument has good construct validity. One advantage to using the MSQLI is that psychometrically sound short scales are available. Furthermore, when compared to the FAMS and the MSQoL-54, the MSQLI was most flexible since its components are separable.

**RAYS**

The RAYS scale has three subscales that cover different dimensions of HRQoL (physical, psychological, and social-familial) and each includes 15 self-report items scored from one (best) to four (worse). Validation was achieved through administration of the scale to 50 randomly selected MS patients and to 50 age, sex-, education- and family status-matched healthy controls. The instrument demonstrated high internal consistency and significant discriminative value. The RAYS subscales correlated significantly with the SF-36 scales, and the physical RAYS scale was moderately correlated with EDSS.
Pfennings HRQoL Instrument

Pfennings et al. administered the SF-36; COOP/WONCA Charts—the COOP Charts evaluate overall patient functioning through the use of pictorial representations of functioning levels; and DIP to 162 MS patients. Factor analyses identified two underlying dimensions of HRQoL, relating to ‘physical functioning’ and ‘psychological functioning’. Selection of the three highest loading reliable scales on each factor resulted in a final questionnaire consisting of three scales of the SF-36 and three scales of the DIP. In total 40 items were selected, requiring about 10 min to complete. This instrument is brief and adequately measures two dimensions of HRQoL.

Quality of Life-Index MS-Version

The Quality of life-Index (QLI) was developed by Ferrans & Powers to measure quality of life in terms of satisfaction with life. The QLI measures both satisfaction and importance regarding various aspects of life. QLI produces five scores: quality of life overall and in four domains (health and functioning, psychological/spiritual domain, social and economic domain, and family). A number of versions of the QLI have been developed for use with various disorders, including MS. The QLI MS-version consists of 72 items covering physical symptoms, emotional and social sphere, sexual problems, and fatigue.

Performance Scales

The Performance Scales are 7-level categorical rating scales with subscales for mobility, hand function, vision, fatigue, cognitive, bladder/bowel, sensory and spasticity symptoms. The total number of items is 21. Impact on work productivity is assessed with separate items. This instrument has documented test-retest reliability and internal consistency reliability. However, it may be subject to recall bias as patient is asked to compare level of disability to function prior to disease.

HRQoL ASSESSMENT AS END-POINTS IN MS CLINICAL TRIALS

Rapid development of potentially disease-modifying treatments has led to multiple drug trials in patients with both relapsing-remitting and secondary progressive MS. Unfortunately, not all groups have recognized the need to measure the possible benefits of treatment upon broadly defined patient and caregiver well-being. In the last few years, HRQoL assessments have gradually been incorporated into randomized controlled trials to evaluate the effectiveness of MS therapies, such as interferon. Although the use of HRQoL scales provides additional information that is important for treatment decisions and resource allocation, only a handful of Trialists have employed these measures as primary or secondary end-point in MS studies (table 3).

HRQoL findings in randomized clinical trials of new drug treatments for MS

Despite the advent of several MS-specific HRQoL instruments, all except one of the studies of interferon β in relapsing-remitting MS patients have used a generic instrument. Results vary, ranging from no effect on HRQoL to definite improvement in physical dimensions. The reasons for the discrepancy in results is almost certainly related to methodological variations in the samples and their follow-up compounded by the use of different HRQoL instruments. Two studies have evaluated the effect of interferon β on secondary progressive MS patients’ HRQoL. In both studies, several HRQoL dimensions improved. There is one study that has evaluated the HRQoL of MS patients who had suffered a relapse treated with intravenous methylprednisolone. There was statistically significant early improvement of EDSS and the Incapacity Status Scale scores and a trend towards improvement in the SF-36 physical and mental composites short of statistical significance. These results suggest that improvement of impairments and disability after treatment with intravenous methylprednisolone for a relapse of MS occurs early, while improvement of subjective health status is delayed.

HRQoL findings in randomized clinical trials of non-pharmacological trials in MS

Exercise training as well as physical rehabilitation, and T’ai chi programme are known to improve MS patients’ HRQoL (see table 3). Therefore, this data supports the suggestion that patients should be encouraged to engage in regular daily exercise and patients who have significant disability should be offered rehabilitation programmes.

RELATIONSHIP BETWEEN CLINICAL VARIABLES AND HRQoL IN MS

The relationship between clinical variables and HRQoL in MS should be of considerable interest to clinicians since a knowledge of this relationship may
### Table 3  Therapeutic interventions on MS in which a HRQoL instrument has been used

<table>
<thead>
<tr>
<th>Therapy</th>
<th>MS type</th>
<th>Patients</th>
<th>Duration</th>
<th>Instrument</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerobic training</td>
<td>RR</td>
<td>54</td>
<td>15 weeks</td>
<td>SIP</td>
<td>All domains improved</td>
</tr>
<tr>
<td>Rehabilitation programme</td>
<td>PP/SP</td>
<td>43</td>
<td>NS</td>
<td>LLQ</td>
<td>All domains improved</td>
</tr>
<tr>
<td>Outpatient Rehabilitation programme</td>
<td>PP/SP</td>
<td>31</td>
<td>12 months</td>
<td>SF-36</td>
<td>The treatment group showed improvements in six dimensions that were not improved in the wait-listed group</td>
</tr>
<tr>
<td>Schwartz et al.</td>
<td>RR</td>
<td>79</td>
<td>12 months</td>
<td>Q-TWIST</td>
<td>No effect on the number of months of quality-adjusted time</td>
</tr>
<tr>
<td>Rehabilitation programme</td>
<td>PP/SP</td>
<td>33</td>
<td>5 – 10 days</td>
<td>NHP</td>
<td>Overall post-treatment NHP-1 scores were significantly better than overall pretreatment scores for MS patients</td>
</tr>
<tr>
<td>Intrathecal baclofen for spasticity</td>
<td>SP</td>
<td>15</td>
<td>12 months</td>
<td>SF-36</td>
<td>No effect on QLI scores, but the SIP revealed significant changes in the total score as well as the physical and psychosocial subscales.</td>
</tr>
<tr>
<td>INF a 2-a</td>
<td>RR</td>
<td>97</td>
<td>12 months</td>
<td>QLI, SIP</td>
<td>The adverse events negatively affected the patients’ HRQoL</td>
</tr>
<tr>
<td>T’ai chi programme</td>
<td>PP/SP</td>
<td>19</td>
<td>8 months</td>
<td>SF-36</td>
<td>Patients experienced improvements in vitality, social functioning, mental health, and ability to carry out physical and emotional roles.</td>
</tr>
<tr>
<td>Inpatient rehabilitation</td>
<td>RR</td>
<td>50</td>
<td>15 weeks</td>
<td>SF-36</td>
<td>Mental domain improved at 3 and 9 weeks</td>
</tr>
<tr>
<td>Inpatient rehabilitation</td>
<td>PP/SP</td>
<td>50</td>
<td>12 months</td>
<td>SF-36</td>
<td>The effect of inpatient rehabilitation on disability and HRQoL declined after discharge Physical, social and health dimensions improved especially those with an EDSS &lt; 3.0 Interferon β 1b produces important occasional short term QoL gains, but small gains in quality-adjusted life years and large additional costs</td>
</tr>
<tr>
<td>Interferon β 1b</td>
<td>RR</td>
<td>117</td>
<td>60 months</td>
<td>SF-36</td>
<td>Physical dimensions improved. More pain within the first month of treatment Physical dimension improved Trends for improvement of physical and mental composites</td>
</tr>
<tr>
<td>Interferon β 1b</td>
<td>RR</td>
<td>102</td>
<td>12 months</td>
<td>MSQoL-54, EQ-5D</td>
<td>Interferon β 1b produces important occasional short term QoL gains, but small gains in quality-adjusted life years and large additional costs</td>
</tr>
<tr>
<td>Interferon β</td>
<td>RR</td>
<td>51</td>
<td>6 months</td>
<td>SF-36</td>
<td>Physical dimensions improved. More pain within the first month of treatment Physical dimension improved Trends for improvement of physical and mental composites</td>
</tr>
<tr>
<td>Interferon β 1b</td>
<td>SP</td>
<td>718</td>
<td>36 months</td>
<td>SIP</td>
<td>Physical dimension improved Trends for improvement of physical and mental composites</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>RR</td>
<td>24</td>
<td>3 months</td>
<td>SF-36</td>
<td>Physical dimension improved Trends for improvement of physical and mental composites</td>
</tr>
<tr>
<td>Energy conservation course</td>
<td>RR</td>
<td>54</td>
<td>19 weeks</td>
<td>SF-36</td>
<td>HRQoL improved Benefit on eight of 11 MSQoL subscales All domains improved</td>
</tr>
<tr>
<td>Intramuscular interferon β 1a</td>
<td>SP</td>
<td>436</td>
<td>24 months</td>
<td>MSQoL</td>
<td>HRQoL improved Benefit on eight of 11 MSQoL subscales All domains improved</td>
</tr>
<tr>
<td>Outpatient rehabilitation programme</td>
<td>PP/SP</td>
<td>58</td>
<td>6 weeks</td>
<td>SF-36</td>
<td>All domains improved</td>
</tr>
<tr>
<td>Intramuscular interferon β 1a</td>
<td>RR</td>
<td>121</td>
<td>12 months</td>
<td>SF-36</td>
<td>No negative effect on MS patient’s HRQoL.</td>
</tr>
</tbody>
</table>

EQ-5D: European Quality of Life Scale (EuroQoL-5D); LLQ: Laman & Lankhorst Questionnaire; RR: Remitting-Relapsing; SP: Secondary Progressive; PP: Primary Progressive; SF-36: 36-Item Short-Form Health Survey; QLI: Ferrans and Powers Quality of Life Index; SIP: Sickness Impact Profile; MSQoL: Multiple Sclerosis Quality of Life Inventory; MSQoL-54: Multiple Sclerosis Quality of Life 54; NHP: Nottingham Health Profile; NS: Non-stated.
permit identification of those aspects of disease most closely linked with patient-rated distress and thus inform targeted treatment.

Relationship between neurological impairment and disability and HRQoL

A substantial body of evidence demonstrates that HRQoL in MS is associated with impairment and disability as measured by neurological symptoms, the EDSS or the Multiple Sclerosis Functional Composite.98–106 However, the strength of the correlation varies enormously depending on the methodology of each individual study. In a Canadian study involving 198 MS patients, QoL scores for all eight scales of the SF-36 were substantially reduced early in the disease.107 In another study involving 98 patients with MS, measures of bodily function, but not EDSS per se was correlated with QoL scores on the SF-36.108 It is possible to conclude that neurological impairment and disability only contribute a modest proportion to overall HRQoL. However, this association is not negated when other important variables such as fatigue, cognitive impairment, anxiety and depression are accounted for.101 Thus disability appears to have an independent, if modest, contribution to overall HRQoL and over time other variables such as copying style, neuropsychiatric complications and support probably become more significant.21, 101

Given the widespread use of neuroimaging as a marker of disease severity, it should be no surprise that some groups have reported a similar modest link with HRQoL. For example, in a recent magnetic resonance imaging (MRI) study, brain lesions and atrophy were associated with impaired several domains of HRQoL including sexual dysfunction, poor mental health, and functional limitations. These correlations were stronger for hypointense lesions and atrophy on T1-weighted images than for hyperintense lesions on T2-weighted images.98 What is not yet known, is whether neuroimaging can explain a significant proportion of HRQoL over and above that explained by a clinically based patient evaluation.

Relationship between disease course and subtype and HRQoL

There is some debate regarding the influence of the physical symptoms of MS on HRQoL. While, those living a longer time with MS are likely to have increased levels of disability, poor psychological adjustment to MS is not necessarily related to a longer disease duration or high disease severity.109–111 Nevertheless, disease course may influence HRQoL. Specifically, the more aggressive the disease course, the lower the HRQoL. Thus, all other factors being equal, a primary progressive subtype has more negative impact than a secondary progressive subtype which in turn has more negative impact than a relapsing–remitting subtype.86, 70 It must also be recognised that all subtypes have a haphazard element which is difficult for patients to cope with.

Relationship between cognitive impairment and HRQoL

The prevalence of cognitive impairment in MS is estimated at 45–65% and is a feature of all disease subtypes, including groups of patients with normal appearing white matter.112 Varying degrees of mild cognitive impairment are much more common than frank dementia. Patients with cognitive impairment are less likely to be professionally and socially active and are more dependent on caregivers than cognitively intact MS patients.113 The majority of studies clearly show an association between cognitive impairment and global HRQoL. For example, executive dysfunction and memory impairment are related to a worsening of HRQoL (in particular the physical functioning and mental health subscales of SF-36).114 In line with these results, in a recent study involving 209 MS patients our group found that the worse cognitive functioning the lower HRQoL.70 However one notable exception found an inverse relationship between HRQoL and cognitive function. Severely affected MS patients with autobiographical impaired memory reported significantly better HRQoL.115 One explanation may be the interplay with insight. Patients with significantly impaired cognition tend to have reduced insight into their condition. In this study, patients with normal autobiographical memory reported the highest levels of depression and the lowest levels of HRQoL. Thus it may be that the negative aspects of impaired cognition on HRQoL were offset by poor insight and the advantages of good cognition on HRQoL were confounded by low mood.

Relationship between depression and HRQoL

Mood disorders, particularly depression and anxiety are very common in MS patients but frequently overlooked.116 Depression shows one of the strongest links with lower HRQoL scores in several studies, independent of the clinical course or disability status of MS patients.70, 116–122 MS depressed patients scored worse in the energy, mental health, cognitive function, overall
QoL, sexual and emotional function dimensions than non-depressed MS patients. In a recent paper, a strong inverse correlation was found between the physical and mental dimensions and the depressive symptoms was found using the MSQOL-54 and the Hamilton Depression Rating Scale. Furthermore, a highly significant correlation between depressive symptoms using the Zung Depression Scale, as well as anxiety using the Zung Anxiety Scale, and the self-assessed quality of life measured with a generic instrument (QoL index). The negative impact of depression on HRQoL has also been demonstrated by our group. Bakshi et al. found that depression was significantly associated with lower HRQoL scores concerning health perception, sexual dysfunction, health distress, mental health, overall QoL, emotional dysfunction, and limitations due to emotional problems. In this study, associations remained significant after adjusting for confounders such as severity of neurologic disability and fatigue. However, there is a conceptual problem in understanding the link between mood and HRQoL. Most scales of HRQoL include ratings of mood, satisfactions and somatic items which are also symptoms of depression. Fundamentally, patients who are currently depressed will give a greater negative evaluation of their wellbeing than those who are not depressed, whether or not a physical illness is also present. Thus it is unavoidable that there will be some overlap between ratings of low mood and HRQoL. However, the association may still prove clinically useful if the depression provides a contribution to HRQoL beyond that explained by other variables or conversely if measures of HRQoL allow greater recognition of depression.

Relationship between fatigue and HRQoL

The subjective experience of fatigue is one of the most common and disabling symptoms in MS patients. Fatigue is certainly linked with reduced HRQoL, however, the precise way in which fatigue impacts on HRQoL has not been clearly defined. In a recent study involving patients with MS, fatigue as well as depression were independently associated with impaired HRQoL. Recently, these findings have been corroborated by our group. Accumulating work suggests that the recognition and treatment of fatigue can improve HRQoL. The overlap of fatigue and depression may be a methodological concern in the assessment of either. However, in a longitudinal assessment of a cohort of 98 MS patients, depression did not predict the later mental fatigue nor was depression predicted by preceding fatigue experiences.

Conclusions

Several factors conspire to make MS a disease with major psychological and social ramifications for both patients and their caregivers. These include the onset of MS during the most productive years of life, the uncertain and unstable natural history of the condition, the diffuse effects on the CNS, especially on higher functions, the relative preservation of insight and the absence of convincing disease-modifying treatment. Historically, the assessment of MS has encompassed measures that assess impairment and disability but has omitted important components of HRQoL as volunteered by sufferers themselves. In the last few years, a greater understanding of HRQoL in MS has facilitated several clinical advances. Generic and specific HRQoL instruments have been developed and validated in order to more accurately determine the global impact of MS on an individual and along with the relevant predictive factors. Clinical trials of new pharmacological and non-pharmacological treatments have begun to incorporate HRQoL measures as primary or secondary outcome points. There is now considerable interest in understanding the predictors of HRQoL. Perhaps surprisingly, established physician rated measures of impairment and disability are not as closely linked with HRQoL as patient ratings of handicap and mood. Of particular note, depression has one of the strongest associations with low HRQoL and also influences engagement in rehabilitation and level of distress in caregivers. These findings have been replicated in other neurological diseases. Greater awareness of such influences upon HRQoL is likely to lead to better recognition and treatment of previously overlooked neuropsychiatric complications. Yet the overlap between neuropsychiatric syndromes and HRQoL in its current form, remains a difficult conceptual area. For example, cognitive deficits are a manifestation of MS and a predictor of poor HRQoL but such complaints, when severe, may interfere with self-evaluation. Similarly low mood is a common complication of MS and logically linked with low HRQoL, but depression is likely to disproportionately affect global self-evaluation and hence influence different domains of HRQoL. A simple solution is to allow any complaint, or limitation into a global rating of HRQoL, accepting that each complication adds to the burden of disease as a whole. A more challenging solution is to ask how much does the complication uniquely interfere with that individual’s premorbid expectation of their ability to act, think and feel. For example, one might equally ask to what extent does low mood interfere with a patient’s ability to enjoy
seeing friends, as to what extent does the ataxia interfere with the ability to leave the house, unaided. In this sense the impact of a disease will always be more than the total collection of symptoms using any method of measurement. What is more, only the sufferers themselves can attempt to estimate the past, present and anticipated future losses that are causing distress.

We have seen a proliferation of generic and specific HRQoL scales for MS over the last 10 years. It is now time to examine their properties carefully in order to find the scales most suitable for specific situations. It is unlikely that one scale will satisfy all requirements. Most notably clinicians need a concise scale, that can be administered by members of a multidisciplinary team and junior medical staff. Researchers generally need a more comprehensive scale that is particularly sensitive to change. Future developments in this field will include a better delineation of the modifying variables in HRQoL. These may include the impact of doctor-patient communication, availability of local resources, the effect of self-help and education strategies, the influence of support and the effects of individual differences in coping and adjustment to illness. HRQoL is now established as an important outcome variable in therapeutic trials in MS where it often highlights areas of most concern to patients and care-givers. The concept of HRQoL is equally important in clinical practice as it emphasizes the importance of neuropsychiatric and social complications as well as the traditional impairment and disability domains that form part of the total burden experienced by patients with MS.

References
2 Rivera-Navarro J, Morales JM, Benito-León J. Informal caregiving in multiple sclerosis patients: Data from the demyelinating diseases study group from Madrid. Disability and Rehabilitation; (in press).
Impact of MS on health-related quality of life


J. Benito-León et al.


127 Lou RS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. *Neurology* 2003; 60: 122 – 123.


**AUTHOR:** The following queries have arisen during the editing of your manuscript. Please answer the queries by marking the requisite corrections at the appropriate positions in the text.

<table>
<thead>
<tr>
<th>QUERY NO.</th>
<th>QUERY DETAILS</th>
<th>QUERY ANSWERED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Knight et al 1997 (Reference 129) is not cited in text</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Please supply any further details</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Please supply full journal title</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Please supply all authors</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Reference 60. Please confirm if this is a single page or a page span</td>
<td></td>
</tr>
</tbody>
</table>